drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Donor-derived T lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD70, administered intrathecally to eliminate CD70-positive glioma cells via CAR-mediated T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Donor-derived T cells engineered with a CD70-specific chimeric antigen receptor recognize CD70 on glioma cells independently of MHC, triggering CAR-mediated T-cell activation (CD3ΞΆ with costimulation) and effector functions, including perforin/granzyme cytotoxicity and cytokine release, to eliminate CD70-positive tumor cells; administered intrathecally for CNS delivery.
drug_name
Allogeneic CD70-directed CAR T cells
nct_id_drug_ref
NCT06828341